Alnylam Pharmaceuticals
ALNY
#650
Rank
C$55.18 B
Marketcap
C$413.35
Share price
-0.61%
Change (1 day)
-7.35%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): C$5.27

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is C$5.38. In 2025 the company made an earnings per share (EPS) of C$2.55.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)C$5.27106.41%
2025C$2.55
2023C-$5.01-62%
2022C-$13.1829.03%
2021C-$10.21-3.36%
2020C-$10.57-8.48%
2019C-$11.557.67%
2018C-$10.7339.74%
2017C-$7.6712.94%
2016C-$6.8038.84%
2015C-$4.89-32.88%
2014C-$7.29259.44%
2013C-$2.03-31.25%
2012C-$2.95

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
C$9.96 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$3.63-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$60.34 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
C-$11.80-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
C-$1.04-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
C-$0.34-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$1.94-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C$0.50-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA